Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  London Stock Exchange  >  Allergy Therapeutics plc    AGY   GB00B02LCQ05

ALLERGY THERAPEUTICS PLC

(AGY)
  Report
Delayed Quote. Delayed London Stock Exchange - 01/27 11:35:28 am
19.55 GBX   -0.76%
01/14ALLERGY THERAPEUTICS : Half Year Trading Update 2021 and Notice of Results
AQ
2020ALLERGY THERAPEUTICS : 2020 AGM Poll Vote Results
PU
2020ALLERGY THERAPEUTICS : Notice of Meeting
PU
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed London Stock Exchange
01/21/2021 01/22/2021 01/25/2021 01/26/2021 01/27/2021 Date
20.1(c) 19.25(c) 19.45(c) 19.7(c) 19.55 Last
188 111 228 766 151 329 280 277 89 435 Volume
+1.26% -4.23% +1.04% +1.29% -0.76% Change
More quotes
Financials
Sales 2021 83,4 M 114 M 114 M
Net income 2021 -4,55 M -6,22 M -6,22 M
Net cash position 2021 29,5 M 40,4 M 40,4 M
P/E ratio 2021 -27,2x
Yield 2021 -
Sales 2022 88,2 M 121 M 121 M
Net income 2022 -6,01 M -8,23 M -8,23 M
Net cash position 2022 18,9 M 25,8 M 25,8 M
P/E ratio 2022 -20,7x
Yield 2022 -
Capitalization 125 M 172 M 171 M
EV / Sales 2021 1,15x
EV / Sales 2022 1,21x
Nbr of Employees -
Free-Float 13,8%
More Financials
Company
Allergy Therapeutics Plc is a pharmaceutical company. The Company focuses on the treatment and prevention of allergy with aluminum-free products. The Company's segments are Central Europe, which includes segments, such as Germany, Australia, Switzerland and the Netherlands; Southern Europe, which includes Italy and Spain; the United Kingdom, and Rest of World. The Company provides information to healthcare... 
Sector
Pharmaceuticals
Calendar
03/03Earnings Release
More about the company
Notations Surperformance© of Allergy Therapeutics plc
Trading Rating : Investor Rating :
More Ratings
All news about ALLERGY THERAPEUTICS PLC
01/14ALLERGY THERAPEUTICS : Half Year Trading Update 2021 and Notice of Results
AQ
2020ALLERGY THERAPEUTICS : 2020 AGM Poll Vote Results
PU
2020ALLERGY THERAPEUTICS : Notice of Meeting
PU
2020ALLERGY THERAPEUTICS :  Allergy Therapeutics plc Preliminary Results for the yea..
AQ
2020ALLERGY THERAPEUTICS : Block listing six monthly return
AQ
2020ALLERGY THERAPEUTICS : Trading Update
AQ
2020ALLERGY THERAPEUTICS : welcomes European Academy of Allergy and Clinical Immunol..
AQ
2020ALLERGY THERAPEUTICS : Half-year Report
PU
2019ALLERGY THERAPEUTICS : Allergy Therapeutics announces update to Grass MATA MPL p..
AQ
2019ALLERGY THERAPEUTICS : Result of Annual General Meeting
AQ
2019ALLERGY THERAPEUTICS PLC : half-yearly earnings release
2018ALLERGY THERAPEUTICS PLC : annual earnings release
2018ALLERGY THERAPEUTICS PLC : half-yearly earnings release
2017ALLERGY THERAPEUTICS PLC : annual earnings release
2017ALLERGY THERAPEUTICS PLC : annual sales release
More news
News in other languages on ALLERGY THERAPEUTICS PLC
2019ALLERGY THERAPEUTICS : veröffentlicht Update zur Geschäftsentwicklung
2019Allergy Therapeutics plc veröffentlicht Update zur Geschäftsentwicklung
2019ALLERGY THERAPEUTICS : gibt Update zur Geschäftsentwicklung und Produkt-Pipeline
2019Allergy Therapeutics gibt Update zur Geschäftsentwicklung und Produkt-Pipelin..
2019ALLERGY THERAPEUTICS PLC : plonge de 37% après un échec en phase III
More news
Chart ALLERGY THERAPEUTICS PLC
Duration : Period :
Allergy Therapeutics plc Technical Analysis Chart | AGY | GB00B02LCQ05 | MarketScreener
Technical analysis trends ALLERGY THERAPEUTICS PLC
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 5
Average target price 50,00 GBX
Last Close Price 19,70 GBX
Spread / Highest target 255%
Spread / Average Target 154%
Spread / Lowest Target 77,7%
EPS Revisions
Managers and Directors
NameTitle
Manuel Llobet Chief Executive Officer & Executive Director
Peter Sinclair Jensen Non-Executive Chairman
Bev Lees Group Director-Operations
Nicolas Alexander Ulrich Wykeman Chief Financial Officer & Executive Director
Murray Skinner Chief Scientific Officer
Sector and Competitors
1st jan.Capitalization (M$)
ALLERGY THERAPEUTICS PLC18.50%173
JOHNSON & JOHNSON8.32%448 796
ROCHE HOLDING AG4.51%312 213
NOVARTIS AG0.81%214 457
PFIZER INC.1.36%207 384
MERCK & CO., INC.-1.89%203 035